EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Analysis of Pseudomonas aeruginosa Infections in Children Undergoing Chemotherapy or Hematopoietic Cell Transplantation: A Multicenter Nationwide Study

Klinische Analyse von Pseudomonas-aeruginosa-Infektionen bei Kindern unter Chemotherapie oder hämatopoetischer Zelltransplantation: multizentrische landesweite Studie

Monika Richert-Przygońska iD, Krzysztof Czyżewski, Patrycja Zalas-Więcek, Olga Gryniewicz-Kwiatkowska, Agnieszka Gietka, Zofia Małas, Katarzyna Semczuk, Liliana Chełmecka, Iwona Żak iD, Małgorzata Salamonowicz-Bodzioch, Jowita Frączkiewicz, Olga Zając-Spychała iD und 18 weitere

Journal of Clinical Medicine · 26.05.2025 · 14 (11) · 3714

DOI: 10.3390/jcm14113714 ↗

Auf einen Blick

Bei Kindern unter Chemotherapie oder hämatopoetischer Zelltransplantation war die kumulative Inzidenz von Pseudomonas-aeruginosa-Infektionen ähnlich. Die Überlebensrate nach Infektion war in der HCT-Gruppe niedriger.

Fragestellung

Wie häufig treten Pseudomonas-aeruginosa-Infektionen bei Kindern unter Chemotherapie oder hämatopoetischer Zelltransplantation auf, und unterscheiden sich Erregerlage und Verlauf?

Methode

Retrospektive multizentrische landesweite Analyse von Kindern in 17 polnischen PHO-Zentren und 6 pädiatrischen HCT-Zentren von 2014–2023.

Ergebnisse

Analysiert wurden 1.629 HCTs und 9.614 neu diagnostizierte Kinder mit Neoplasien. PSA-Inzidenz: 6,71 % in PHO vs. 6,32 % in HCT (p = 0,624). Überleben nach PSA-Infektion: 89,3 % vs. 96,0 % (p = 0,004).

Schlussfolgerung der Autor:innen

Obwohl das Infektionsrisiko und das Auftreten resistenter Stämme in HCT-Patient:innen vergleichbar waren, war das Ergebnis der PSA-Infektionen im PHO-Setting besser.

Kernaussagen

  • PSA-Inzidenz ähnlich: 6,71 % in PHO vs. 6,32 % in HCT
  • Überleben nach PSA-Infektion niedriger in HCT: 89,3 % vs. 96,0 %
  • Meropenem und Ceftazidim waren häufige antipseudomonale Therapien

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 26.05.2025. Verfasst von Monika Richert-Przygońska und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, 85-094 Bydgoszcz, Poland. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pseudomonas aeruginosa (PSA) infections are associated with a high recurrence rate and high mortality in immuno-compromised patients. There are limited studies regarding pediatric hematopoietic cell transplantation recipients.

Aim

The nationwide multicenter study was conducted to analyze the epidemiology of PSA infections in children treated with chemotherapy (PHO, pediatric hematology and oncology) or undergoing hematopoietic allogeneic or autologous cell transplantation (HCT) in the period 2014–2023.

Methods

We retrospectively analyzed the clinical and microbiological data of children who underwent anticancer therapy or hematopoietic cell transplantation in 17 Polish PHO centers and six pediatric HCT centers. The data were collected in two-year intervals.

Results

During the 10-year study period, a total of 1629 HCTs (both autologous and allogeneic) and 9614 children newly diagnosed with neoplasms were analyzed. The cumulative incidence of PSA infection was similar in both groups (6.71% in PHO vs. 6.32% in HCT, p = 0.624). The total number of PSA bloodstream infections was comparable in the PHO and HCT groups (31.9% vs. 26.2%; p = 0.223). In both analyzed groups, the antipseudomonal drugs of choice were as follows: meropenem, ceftazidime, and tazobactam/piperaciline in combination with other antibiotics. In the HCT group, high rates of meropenem (20.4%) and tazobactam/piperaciline (18.4%) non-susceptibility were observed. This led to colistin therapy in 5.3% of patients. There was no difference in the median antibiotic therapy time in both groups; however, the survival rates from PSA infection were significantly lower in the HCT group (89.3% vs. 96.0%, p = 0.004).

Conclusions

Although the risk of infection and the occurrence of resistant bacterial strains in HCT patients were comparable with those in PHO patients, the outcome of PSA infections was better in the PHO setting.

Schlagwörter

Stichwörter der Autor:innen

Pseudomonas aeruginosachildrenhematopoietic cell transplantation

Autor:innen und Institutionen

  • Department of Pediatrics, Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University Torun, 85-094 Bydgoszcz, Poland.
  • Department of Microbiology, Collegium Medicum, Nicolaus Copernicus University Torun, 85-094 Bydgoszcz, Poland.
  • Department of Oncology, Children's Memorial Health Institute, 04-730 Warsaw, Poland.
  • Department of Microbiology, Children's Memorial Health Institute, 04-730 Warsaw, Poland.
  • Department of Pediatric Oncology and Hematology, University Children's Hospital, Jagiellonian University, Collegium Medicum, 31-008 Krakow, Poland.
  • Department of Microbiology, University Children's Hospital, 31-008 Krakow, Poland.

ORCID-Profile: Monika Richert-Przygońska, Iwona Żak, Olga Zając-Spychała, Ewa Bień, Anna Szmydki-Baran, Agnieszka Zaucha-Prażmo, Jan Styczyński

Zitieren

APA

Richert-Przygońska, M., Czyżewski, K., Zalas-Więcek, P., Gryniewicz-Kwiatkowska, O., Gietka, A., Małas, Z., Semczuk, K., Chełmecka, L., Żak, I., Salamonowicz-Bodzioch, M., Frączkiewicz, J., Zając-Spychała, O., Bień, E., Irga-Jaworska, N., Płonowski, M., Wawryków, P., Bartnik, M., Pierlejewski, F., Gamrot, Z., …, & Polish Society of Pediatric Oncology and Hematology (2025). Clinical Analysis of Pseudomonas aeruginosa Infections in Children Undergoing Chemotherapy or Hematopoietic Cell Transplantation: A Multicenter Nationwide Study. Journal of Clinical Medicine, 14(11), 3714. https://doi.org/10.3390/jcm14113714

Vancouver

Richert-Przygońska M, Czyżewski K, Zalas-Więcek P, Gryniewicz-Kwiatkowska O, Gietka A, Małas Z, et al. Clinical Analysis of Pseudomonas aeruginosa Infections in Children Undergoing Chemotherapy or Hematopoietic Cell Transplantation: A Multicenter Nationwide Study. Journal of Clinical Medicine. 2025;14(11):3714. doi:10.3390/jcm14113714

BibTeX
@article{RichertPrzygoska2025,
  author = {Richert-Przygońska, Monika and Czyżewski, Krzysztof and Zalas-Więcek, Patrycja and Gryniewicz-Kwiatkowska, Olga and Gietka, Agnieszka and Małas, Zofia and Semczuk, Katarzyna and Chełmecka, Liliana and Żak, Iwona and Salamonowicz-Bodzioch, Małgorzata and Frączkiewicz, Jowita and Zając-Spychała, Olga and Bień, Ewa and Irga-Jaworska, Ninela and Płonowski, Marcin and Wawryków, Paweł and Bartnik, Magdalena and Pierlejewski, Filip and Gamrot, Zuzanna and Badowska, Wanda and Stolpa, Weronika and Musiał, Jakub and Szmydki-Baran, Anna and Hutnik, Łukasz and Tomaszewska, Renata and Urbanek-Dądela, Agnieszka and Zaucha-Prażmo, Agnieszka and Goździk, Jolanta and Styczyński, Jan and Polish Society of Pediatric Oncology and Hematology, Polish Society of Pediatric Oncology and Hematology},
  title = {Clinical Analysis of Pseudomonas aeruginosa Infections in Children Undergoing Chemotherapy or Hematopoietic Cell Transplantation: A Multicenter Nationwide Study},
  journal = {Journal of Clinical Medicine},
  year = {2025},
  volume = {14},
  number = {11},
  pages = {3714},
  doi = {10.3390/jcm14113714}
}
Kostenlos starten →